What is the role of lapatinib in the treatment of renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

Lapatinib is an epidermal growth factor receptor (EGFR) and ErbB-2 dual tyrosine kinase inhibitor that appears to have efficacy in the treatment of tumors that overexpress EGFR, including renal cell carcinoma. A phase 3 study in patients with advanced  RCC whose disease had failed previous therapy found that lapatinib was well tolerated and had overall efficacy equivalent to that of hormonal therapy. [62]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!